MediLink, a development partner of Roche Holding, announced that its Phase III study of Tam-Peli in patients with relapsed small-cell lung cancer met its primary endpoints. The trial reported a 54% reduction in the risk of death and a 71% decrease in disease progression compared with the chemotherapy agent topotecan. Objective response rates were 59.1% for Tam-Peli versus 9.7% for the comparator.
Roche holds worldwide rights to Tam-Peli outside mainland China, Hong Kong and Macau. The results bolster Roche’s oncology pipeline, which also includes late‑stage candidates giredestrant and fenebrutinib.
In a separate development, the U.S. Food and Drug Administration granted priority review to Roche’s drug Enspryng for the rare autoimmune condition MOGAD, with a decision expected by Jan. 10, 2027. The European Medicines Agency is targeting a third‑quarter 2027 timeline for its review.
Roche Holding, valued at roughly CHF 275.1 billion, is currently priced below its fair‑value estimate of CHF 370, according to analysts cited in the source.
